Results 201 to 210 of about 181,985 (340)

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a
Anna Lundahl   +11 more
wiley   +1 more source

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials. [PDF]

open access: yesMed Mycol
Kawasaki A   +12 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort   +8 more
wiley   +1 more source

Pharmacokinetic profiles of sertraline in pregnancy as a predictor of postpartum depressive symptoms

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To characterize pharmacokinetic changes of sertraline and its metabolite during pregnancy and postpartum, and their relationship to maternal postpartum depressive symptoms. Methods This was a prospective observational, longitudinal study of pregnant women with a major depressive disorder treated with sertraline (N = 185 women, 205 pregnancies ...
Sílvia M. Illamola   +8 more
wiley   +1 more source

Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ9‐tetrahydrocannabinol in older patients with poor appetite

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Cannabis‐based medicines are gaining interest and being explored for new therapeutic indications, many of which commonly affect older medical patients. As most previous studies of the population pharmacokinetics of cannabinoids have been performed in healthy adults, this study aimed to investigate the population pharmacokinetics of Δ9 ...
Ida Klitzing Storgaard   +12 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Editorial: Diverse functions of drug transporters. [PDF]

open access: yesFront Pharmacol
Granados JC, Cheung KWK, Prasad B.
europepmc   +1 more source

Challenges in optimizing tacrolimus therapy in patients treated with rifampin: A case series

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Tacrolimus is a cornerstone immunosuppressant in transplantation medicine with a narrow therapeutic window. Drug–drug interactions with strong CYP3A4 and P‐glycoprotein modulators, such as rifampin and azole antifungals, significantly alter tacrolimus exposure and complicate therapy. Two transplant cases illustrates the impact of rifampin on tacrolimus
Jeroen P. A. Houwen   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy